<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration under Section 12(g)
of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports
Under Section 13 and 15(d) of the Securities Exchange Act of 1934.
Commission File Number 0-21696
ARIAD Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
26 Landsdowne Street
Cambridge, Massachusetts 02139
(617) 494-0400
------------------------------------------------------------------------
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
Series A Preferred
Stock Purchase Rights
--------------------------------------------------------
(Title of each class of Securities covered by this Form)
Common Stock, par value $.001 per share
---------------------------------------------------------------------------
(Titles of all other classes of securities for which a duty to
file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s)
relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) [X] Rule 12h-3(b)(1)(i) [ ]
Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(1)(ii) [ ]
Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(ii) [ ] Rule 12h-3(b)(2)(ii) [ ]
Rule 15d-6 [ ]
-1-
<PAGE> 2
Approximate number of holders of record as of the certification or notice
date: 0
Pursuant to the requirements of the Securities Exchange Act of 1934 ARIAD
Pharmaceuticals, Inc. has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.
Date: June 19, 2000 By: /s/ Jay R. Lamarche
-------------------
Name: Jay R. LaMarche
Title: Treasurer
-2-
